Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome

Jong Youn Kim, Donghoon Choi, Young Guk Ko, Sungha Park, Yangsoo Jang, Do Yun Lee

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background/Purpose: May-Thurner syndrome is an uncommon disease entity in which the left common iliac vein is compressed by the right common iliac artery with subsequent development of deep vein thrombosis and chronic venous insufficiency. We report our experience on the treatment of extensive iliofemoral deep venous thrombosis due to May-Thurner syndrome using endovascular techniques. Methods: The study group comprised 21 patients (8 men, 13 women; mean age 51 years) diagnosed with May-Thurner syndrome by venogram. Eighteen patients were treated with catheter-guided thrombolysis; 3 patients with short segment involvement did not require thrombolysis. After completion of the thrombolytic therapy, the residual venous narrowing was treated by balloon angioplasty and/or placement of a self-expandable stent. Results: The mean total dose of urokinase was 4.28∈±∈1.89 million units, and the mean duration of infusion was 72∈±∈35 hr. Eighteen of the 21 patients received stent deployment. The mean diameter of the stents was 12.9∈±∈2.0 mm. Initial technical successes with immediate symptom resolution were achieved in 20 of the 21 patients (95%). We performed a follow-up venogram 6 months after procedure and checked clinical symptoms at outpatient clinics (mean follow-up duration 10.8 months). Among the patients who received stent implantation, 2 had recurrent thrombotic occlusion during the follow-up period. Three patients, who did not receive stent implantation, all had recurrent thrombosis. There were no major bleeding complications except in 1 patient who developed retroperitoneal hematoma. Conclusion: Catheter-guided thrombolysis and angioplasty with stent implantation is a safe and effective method for the treatment of May-Thurner syndrome.

Original languageEnglish
Pages (from-to)571-575
Number of pages5
JournalCardiovascular and interventional radiology
Volume29
Issue number4
DOIs
Publication statusPublished - 2006 Aug 1

Fingerprint

May-Thurner Syndrome
Venous Thrombosis
Stents
Therapeutics
Catheters
Iliac Vein
Venous Insufficiency
Endovascular Procedures
Balloon Angioplasty
Iliac Artery
Thrombolytic Therapy
Urokinase-Type Plasminogen Activator
Ambulatory Care Facilities
Angioplasty
Hematoma
Thrombosis
Hemorrhage

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Cite this

@article{5148b6f1901d4c169d3efeb651657815,
title = "Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome",
abstract = "Background/Purpose: May-Thurner syndrome is an uncommon disease entity in which the left common iliac vein is compressed by the right common iliac artery with subsequent development of deep vein thrombosis and chronic venous insufficiency. We report our experience on the treatment of extensive iliofemoral deep venous thrombosis due to May-Thurner syndrome using endovascular techniques. Methods: The study group comprised 21 patients (8 men, 13 women; mean age 51 years) diagnosed with May-Thurner syndrome by venogram. Eighteen patients were treated with catheter-guided thrombolysis; 3 patients with short segment involvement did not require thrombolysis. After completion of the thrombolytic therapy, the residual venous narrowing was treated by balloon angioplasty and/or placement of a self-expandable stent. Results: The mean total dose of urokinase was 4.28∈±∈1.89 million units, and the mean duration of infusion was 72∈±∈35 hr. Eighteen of the 21 patients received stent deployment. The mean diameter of the stents was 12.9∈±∈2.0 mm. Initial technical successes with immediate symptom resolution were achieved in 20 of the 21 patients (95{\%}). We performed a follow-up venogram 6 months after procedure and checked clinical symptoms at outpatient clinics (mean follow-up duration 10.8 months). Among the patients who received stent implantation, 2 had recurrent thrombotic occlusion during the follow-up period. Three patients, who did not receive stent implantation, all had recurrent thrombosis. There were no major bleeding complications except in 1 patient who developed retroperitoneal hematoma. Conclusion: Catheter-guided thrombolysis and angioplasty with stent implantation is a safe and effective method for the treatment of May-Thurner syndrome.",
author = "Kim, {Jong Youn} and Donghoon Choi and {Guk Ko}, Young and Sungha Park and Yangsoo Jang and Lee, {Do Yun}",
year = "2006",
month = "8",
day = "1",
doi = "10.1007/s00270-004-0165-7",
language = "English",
volume = "29",
pages = "571--575",
journal = "CardioVascular and Interventional Radiology",
issn = "7415-5101",
publisher = "Springer Verlag",
number = "4",

}

Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome. / Kim, Jong Youn; Choi, Donghoon; Guk Ko, Young; Park, Sungha; Jang, Yangsoo; Lee, Do Yun.

In: Cardiovascular and interventional radiology, Vol. 29, No. 4, 01.08.2006, p. 571-575.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Percutaneous treatment of deep vein thrombosis in May-Thurner syndrome

AU - Kim, Jong Youn

AU - Choi, Donghoon

AU - Guk Ko, Young

AU - Park, Sungha

AU - Jang, Yangsoo

AU - Lee, Do Yun

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Background/Purpose: May-Thurner syndrome is an uncommon disease entity in which the left common iliac vein is compressed by the right common iliac artery with subsequent development of deep vein thrombosis and chronic venous insufficiency. We report our experience on the treatment of extensive iliofemoral deep venous thrombosis due to May-Thurner syndrome using endovascular techniques. Methods: The study group comprised 21 patients (8 men, 13 women; mean age 51 years) diagnosed with May-Thurner syndrome by venogram. Eighteen patients were treated with catheter-guided thrombolysis; 3 patients with short segment involvement did not require thrombolysis. After completion of the thrombolytic therapy, the residual venous narrowing was treated by balloon angioplasty and/or placement of a self-expandable stent. Results: The mean total dose of urokinase was 4.28∈±∈1.89 million units, and the mean duration of infusion was 72∈±∈35 hr. Eighteen of the 21 patients received stent deployment. The mean diameter of the stents was 12.9∈±∈2.0 mm. Initial technical successes with immediate symptom resolution were achieved in 20 of the 21 patients (95%). We performed a follow-up venogram 6 months after procedure and checked clinical symptoms at outpatient clinics (mean follow-up duration 10.8 months). Among the patients who received stent implantation, 2 had recurrent thrombotic occlusion during the follow-up period. Three patients, who did not receive stent implantation, all had recurrent thrombosis. There were no major bleeding complications except in 1 patient who developed retroperitoneal hematoma. Conclusion: Catheter-guided thrombolysis and angioplasty with stent implantation is a safe and effective method for the treatment of May-Thurner syndrome.

AB - Background/Purpose: May-Thurner syndrome is an uncommon disease entity in which the left common iliac vein is compressed by the right common iliac artery with subsequent development of deep vein thrombosis and chronic venous insufficiency. We report our experience on the treatment of extensive iliofemoral deep venous thrombosis due to May-Thurner syndrome using endovascular techniques. Methods: The study group comprised 21 patients (8 men, 13 women; mean age 51 years) diagnosed with May-Thurner syndrome by venogram. Eighteen patients were treated with catheter-guided thrombolysis; 3 patients with short segment involvement did not require thrombolysis. After completion of the thrombolytic therapy, the residual venous narrowing was treated by balloon angioplasty and/or placement of a self-expandable stent. Results: The mean total dose of urokinase was 4.28∈±∈1.89 million units, and the mean duration of infusion was 72∈±∈35 hr. Eighteen of the 21 patients received stent deployment. The mean diameter of the stents was 12.9∈±∈2.0 mm. Initial technical successes with immediate symptom resolution were achieved in 20 of the 21 patients (95%). We performed a follow-up venogram 6 months after procedure and checked clinical symptoms at outpatient clinics (mean follow-up duration 10.8 months). Among the patients who received stent implantation, 2 had recurrent thrombotic occlusion during the follow-up period. Three patients, who did not receive stent implantation, all had recurrent thrombosis. There were no major bleeding complications except in 1 patient who developed retroperitoneal hematoma. Conclusion: Catheter-guided thrombolysis and angioplasty with stent implantation is a safe and effective method for the treatment of May-Thurner syndrome.

UR - http://www.scopus.com/inward/record.url?scp=33744762220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744762220&partnerID=8YFLogxK

U2 - 10.1007/s00270-004-0165-7

DO - 10.1007/s00270-004-0165-7

M3 - Article

C2 - 16502185

AN - SCOPUS:33744762220

VL - 29

SP - 571

EP - 575

JO - CardioVascular and Interventional Radiology

JF - CardioVascular and Interventional Radiology

SN - 7415-5101

IS - 4

ER -